Dr. Mauro Discusses Drug Adherence Among CML Patients
Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, explains why some patients with CML don't adhere to their medication.
Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, explains why some patients with CML don’t adhere to their medication.
Mauro says once the disease has been treated, there are minimal symptoms. However, the therapies used to treat CML can lead to chronic low-grade adverse events. Since CML treatment is indefinite, this can be challenging for patients to deal with, Mauro says.​
Acalabrutinib Plus Chemoimmunotherapy Improves PFS in Mantle Cell Lymphoma
May 6th 2024Patients with untreated mantle cell lymphoma treated with acalabrutinib plus bendamustine and rituximab had significant improvements in progression-free survival compared with bendamustine and rituximab alone.
